An Open Label, Multicenter Study of DPTX3186 to Evaluate Safety, Tolerability, and Pharmacokinetics in Subjects With Known Wnt Pathway Activated Solid Tumors Where No Other Treatments Exist
Dewpoint Therapeutics
Summary
This is a first-in human clinical study of DPTX3186 in subjects with Wnt-pathway activated solid tumors where no other treatments exist. The study will evaluate safety, pharmacokinetics, and initial activity of DPTX3186, as well as explore pharmacodynamic parameters to identify potential biomarkers of efficacy
Eligibility
- Age range
- 18+ years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: * Histologically or cytologically confirmed solid tumor and tumor types known to be Wnt-pathway activated (such as colorectal cancer, gastric cancer, lung cancer, and triple negative breast cancer) and no other approved treatment options available. * At least one measurable target lesion as defined by RECIST v1.1 on CT, PET/CT, or MRI. * ECOG performance status of 0 or 1. * Physiological conditions that may prevent absorption of an oral medication including but not limited to colostomy and ileostomy. * Age ≥18 years (or ≥ age of majority per local regulation) * Life expect…
Interventions
- DrugDPTX3186
Once daily (single dose of study drug in the morning in fasted conditions) for 4 consecutive days (4 days on) and 3 days off in a cycle of 28 days
Locations (2)
- NEXT San AntonioSan Antonio, Texas
- NEXT VirginiaFairfax, Virginia